Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Issue 1 (11th October 2019)

• Record Type: Journal Article
• Authors: Puigvehí, Marc; Hashim, Dana; Haber, Philipp K.; Dinani, Amreen; Schiano, Thomas D.; Asgharpour, Amon; Kushner, Tatyana; Kakked, Gaurav; Tabrizian, Parissa; Schwartz, Myron; Gurakar, Ahmet; Dieterich, Douglas; Boffetta, Paolo; Friedman, Scott L.; Llovet, Josep M.; Saberi, Behnam
• Is Part Of: American journal of transplantation. Volume 20:Issue 1(2020)
• Page Start: 220
• Page End: 230
• Publication Date: 2019-10-11
• Subjects: clinical research/practice -- liver disease: infectious -- liver disease: malignant -- liver transplantation/hepatology; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.15576
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Hepatitis C virus infection has been the most common etiology in HCC‐related liver transplantation (LT). Since 2014, direct‐acting antivirals (DAAs) have dramatically improved HCV cure. We aimed to study the changing pattern of etiologies and impact in outcome in HCC‐related LT according to HCV treatment‐era through retrospective analysis of the Scientific Registry of Transplant Recipients (SRTR) database (1987‐2017). A total of 27 855 HCC‐related liver transplants were performed (median age 59 years, 77% male). In the DAA era (2014‐2017) there has been a 14.6% decrease in LT for HCV‐related HCC; however, HCV remains the most common etiology in 50% of cases. In the same era, there has been a 50% increase in LT for NAFLD‐related HCC. Overall survival was significantly worse for HCV‐related HCC compared to NAFLD‐related HCC during pre‐DAA era (2002‐2013; P = .031), but these differences disappeared in the DAA era. In addition, HCV patients had a significant improvement in survival when comparing the DAA era with IFN era ( P < .001). Independent predictors of survival were significantly different in the pre‐DAA era (HCV, AFP, diabetes) than in the DAA era (tumor size). HCV‐related HCC continues to be the main indication for LT in the DAA era, but patients' survival has significantly improved and is comparable to that of NAFLD‐related HCC. Abstract : The study evaluates outcomes of deceased donor liver transplant recipients with hepatocellular carcinoma in the United States and identifies in hepatitis C virus–related hepatocellular carcinoma, in the era of direct‐acting antivirals, that current outcomes are comparable to those of nonalcoholic fatty liver disease–related hepatocellular carcinoma.